Application of VHHs as Agonists & Antagonists
Interested in the potential of antagonist/agonist VHH antibodies in treating diseases? Download our application note “PD-L1 VHH as Functional Antagonists”
Isogenica’s
VHH as Agonists & Antagonists Resources
Isogenica’s PD-L1 VHH as
Functional Antagonists
OCTOBER 13, 2021
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its ligands (PD-L1 or PD-L2), is responsible for the regulation of T-cell activation, apoptosis, proliferation and cytokine production. The interaction between PD-1 and PD-L1 can be both beneficial and harmful…
Anti-LRP5/6 VHH inhibits WNT pathway and prevents tumour growth
APRIL 26, 2021
VHH are the variable domain of heavy chain only antibodies. They are small in size (~15 kD) and biophysically robust. With tunable half-lives, these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery…
FAQs
Can VHHs act as agonists or antagonists?
Yes. VHHs can block or activate receptors, including immune checkpoints and GPCRs.
What types of targets are best suited for VHH agonists or antagonists?
Targets requiring precise epitope engagement, such as GPCRs and immune receptors, are particularly well suited.
Can functional activity be screened during discovery?
Yes. Functional screening can be incorporated alongside binding selection to prioritise agonistic or antagonistic behaviour early.
Partnerships at Isogenica
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.
Explore the science behind our antibody discovery platforms
White Paper “Data-Driven Validation of Synthetic VHHs”
This white paper provides a data-driven validation of Isogenica’s synthetic VHH libraries, powered by Colibra® technology. Designed for biotech and pharmaceutical scientists, it demonstrates how these libraries enhance and accelerate drug discovery, particularly in oncology and immunotherapy. DownloadExtending half-lives of VHH antibodies
Because VHHs are small, they can be cleared quickly from the bloodstream. This can be a useful feature for some applications, but often a longer plasma half-life is desirable. DOWNLOADAdvantages of VHH in bi-specifics
To learn more about the application of VHHs in bi-specifics, we have condensed our expertise into a downloadable Application Note. DOWNLOADOptimizing CAR-T and T-cell antibody engagers: a role for VHH single domain antibodies
This whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities. DOWNLOADIsogenica’s PD-L1 VHH as Functional Antagonists
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its ligands (PD-L1 or PD-L2), is responsible for the regulation of T-cell activation, apoptosis, proliferation and cytokine production. DOWNLOADAnti-LRP5/6 VHH inhibits WNT pathway and prevents tumour growth
VHH are the variable domain of heavy chain only antibodies. They are small in size (~15 kD) and biophysically robust. With tunable half-lives, these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery… DOWNLOAD